Dubach U C, Korn A, Raaflaub J
Arzneimittelforschung. 1975;25(12):1967-9.
The multiple-dose pharmacokinetics of 1-(2-endo-hydroxy-3-endo-bornyl)-3-(p-tolyl-sulfonyl)-urea (glibornuride, Glutril¿) was examined in 7 subjects with maturity-onset diabetes treated with the drug over a period of 4 weeks (25 mg every twelve hours). The steady-state levels of glibornuride (maximum and minimum concentrations) were determined experimentally and by calculation (using the pharmacokinetic parameters obtained following oral administration of 50 mg glibornuride on the 1st day of the treatment). There was good agreement between experimental and calculated values. The results afford evidence for the regular pharmacokinetic pattern of glibornuride. There was neither unexpected accumulation of the drug nor diminution of the steady-state levels as might occur as a consequence of induction of microsomal enzymes.
对7名成年型糖尿病患者进行了为期4周（每12小时服用25毫克）的1-(2-内羟基-3-内冰片基)-3-(对甲苯磺酰基)-脲（格列本脲，Glutril®）多剂量药代动力学研究。通过实验和计算（使用治疗第1天口服50毫克格列本脲后获得的药代动力学参数）确定了格列本脲的稳态水平（最高和最低浓度）。实验值与计算值之间吻合良好。结果为格列本脲有规律的药代动力学模式提供了证据。既没有药物的意外蓄积，也没有因微粒体酶诱导而可能出现的稳态水平降低。
